Next Article in Journal
Involvement of Carboxylesterase in Hydrolysis of Propranolol Prodrug during Permeation across Rat Skin
Previous Article in Journal
Polysaccharide-Based Micelles for Drug Delivery
Previous Article in Special Issue
Delivery of Cancer Therapeutics Using Nanotechnology
Article Menu

Export Article

Open AccessReview

The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer

Institute for Cancer Research, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
LipoMedics LLC., Fort Worth, TX 76107, USA
Author to whom correspondence should be addressed.
Pharmaceutics 2013, 5(2), 353-370;
Received: 22 February 2013 / Revised: 16 May 2013 / Accepted: 24 May 2013 / Published: 18 June 2013
(This article belongs to the Special Issue Drug Delivery Using Nanotechnology)
PDF [381 KB, uploaded 18 June 2013]


Triple Negative Breast Cancer, TNBC, a highly aggressive and metastatic type of breast cancer, is characterized by loss of expression of the estrogen receptor (ER), progesterone receptor (PR), and a lack of overexpression of the human epidermal growth factor receptor 2 (HER2). It is a heterogeneous group of tumors with diverse histology, molecular uniqueness and response to treatment. Unfortunately, TNBC patients do not benefit from current anti-HER2 or hormone positive targeted breast cancer treatments; consequently, these patients rely primarily on chemotherapy. However, the 5-year survival rate for woman with metastatic TNBC is less than 30%. As a result of ineffective treatments, TNBC tumors often progress to metastatic lesions in the brain and lung. Brain metastases of invasive breast cancer are associated with 1 and 2 year survival rate of 20% and <2% respectively. Because the only current systemic treatment for TNBC is chemotherapy, alternative targeted therapies are urgently needed to improve the prognosis for TNBC patients. This review is focused on opportunities for developing new approaches for filling the current void in an effective treatment for TNBC patients. View Full-Text
Keywords: nanoparticle; lipoprotein; triple negative breast cancer; targeted therapy nanoparticle; lipoprotein; triple negative breast cancer; targeted therapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Johnson, R.; Sabnis, N.; McConathy, W.J.; Lacko, A.G. The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer. Pharmaceutics 2013, 5, 353-370.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top